Bristol Myers Squibb (BMY) says its cancer drugs Opdivo and Yervoy improved progression-free survival in a Phase 3 trial for ...
Old drugs from Bristol Myers Squibb and Pfizer have delivered what the companies and researchers believe could establish them ...
We recently compiled a list of the 15 Stocks to Invest in with Steady Dividends. In this article, we are going to take a look ...
Bristol Myers Squibb plans to release initial late-stage trial data on Cobenfy in Alzheimer's-related psychosis during the ...
This was the stock's third consecutive day of gains.
Bristol-Myers Squibb Co (BMY) stock saw a modest uptick, ending the day at $57.04 which represents a slight increase of $0.75 or 1.33% from the prior close of $56.29. The stock opened at $56.63 and ...
We came across a bullish thesis on Bristol-Myers Squibb Company (BMY) on Disruptive analytics’ Substack by Magnus Ofstad. In ...
Legacy Private Trust Co. lifted its position in Bristol-Myers Squibb (NYSE:BMY – Free Report) by 3.3% during the 4th quarter, according to the company in its most recent disclosure with the Securities ...
Bristol Myers Squibb CEO Chris Boerner described Cobenfy, a new drug to treat schizophrenia and may also help with bipolar ...
Ameritas Advisory Services LLC increased its holdings in shares of Bristol-Myers Squibb (NYSE:BMY – Free Report) by 9.4% in ...
Bristol-Myers Squibb Co (BMY) stock saw a modest uptick, ending the day at $56.38 which represents a slight increase of $0.47 or 0.84% from the prior close of $55.91. The stock opened at $55.82 and ...
Analyst David Risinger of Leerink Partners reiterated a Buy rating on Bristol-Myers Squibb (BMY – Research Report), retaining the price target ...